ABUS Arbutus Biopharma Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: ABUS

Price (delayed)

$2.84

Market cap

$422.39M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.73

Enterprise value

$343.6M

Arbutus Biopharma Corporation is a biopharmaceutical company primarily dedicated to discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple ...

Highlights
Arbutus Biopharma's revenue has surged by 185% YoY and by 95% QoQ
Arbutus Biopharma's gross profit has surged by 185% YoY and by 95% QoQ
Arbutus Biopharma's equity has increased by 45% YoY but it has decreased by 2.1% QoQ
ABUS's quick ratio has shrunk by 74% YoY and by 63% QoQ
Arbutus Biopharma's net income has decreased by 14% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://arbutusbio.com
Peers: NRC NWBO

Key stats

What are the main financial stats of ABUS
Market
Shares outstanding
148.73M
Market cap
$422.39M
Enterprise value
$343.6M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.55
Price to sales (P/S)
19.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
16.01
Earnings
Revenue
$21.46M
EBIT
-$68.6M
EBITDA
-$66.89M
Free cash flow
-$29.82M
Per share
EPS
-$0.73
Free cash flow per share
-$0.2
Book value per share
$1.12
Revenue per share
$0.14
TBVPS
$1.6
Balance sheet
Total assets
$236.88M
Total liabilities
$71.03M
Debt
$2.54M
Equity
$165.85M
Working capital
$140.29M
Liquidity
Debt to equity
0.02
Current ratio
5.33
Quick ratio
5.15
Net debt/EBITDA
1.18
Margins
EBITDA margin
-311.8%
Gross margin
100%
Net margin
-352.5%
Operating margin
-311.7%
Efficiency
Return on assets
-45.6%
Return on equity
-59.7%
Return on invested capital
-70.2%
Return on capital employed
-33.5%
Return on sales
-319.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ABUS stock price

How has the Arbutus Biopharma stock price performed over time
Intraday
-2.74%
1 week
5.97%
1 month
29.68%
1 year
-13.68%
YTD
-26.99%
QTD
-4.7%

Financial performance

How have Arbutus Biopharma's revenue and profit performed over time
Revenue
$21.46M
Gross profit
$21.46M
Operating income
-$66.88M
Net income
-$75.63M
Gross margin
100%
Net margin
-352.5%
Arbutus Biopharma's revenue has surged by 185% YoY and by 95% QoQ
Arbutus Biopharma's gross profit has surged by 185% YoY and by 95% QoQ
ABUS's operating margin has surged by 61% year-on-year and by 52% since the previous quarter
The net margin has surged by 60% year-on-year and by 49% since the previous quarter

Growth

What is Arbutus Biopharma's growth rate over time

Valuation

What is Arbutus Biopharma stock price valuation
P/E
N/A
P/B
2.55
P/S
19.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
16.01
The company's EPS rose by 24% YoY and by 12% QoQ
Arbutus Biopharma's equity has increased by 45% YoY but it has decreased by 2.1% QoQ
ABUS's price to book (P/B) is 28% higher than its 5-year quarterly average of 2.0 but 15% lower than its last 4 quarters average of 3.0
Arbutus Biopharma's revenue has surged by 185% YoY and by 95% QoQ
The price to sales (P/S) is 46% lower than the 5-year quarterly average of 36.6 and 42% lower than the last 4 quarters average of 34.0

Efficiency

How efficient is Arbutus Biopharma business performance
The company's return on sales has surged by 61% YoY and by 52% QoQ
The ROIC rose by 38% year-on-year and by 21% since the previous quarter
The ROE is up by 28% year-on-year and by 13% since the previous quarter
Arbutus Biopharma's return on assets has increased by 26% YoY and by 16% QoQ

Dividends

What is ABUS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ABUS.

Financial health

How did Arbutus Biopharma financials performed over time
ABUS's total liabilities has surged by 121% year-on-year and by 103% since the previous quarter
ABUS's quick ratio has shrunk by 74% YoY and by 63% QoQ
The debt is 98% smaller than the equity
Arbutus Biopharma's equity has increased by 45% YoY but it has decreased by 2.1% QoQ
ABUS's debt to equity is down by 33% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.